GlassScriptPhysician profile
Napoleon B Higgins
NPI 1801814363
$718,588.54
in general payments reported to CMS, 2019-2025
32 companies · $269K in 2025
The $269K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $23K · 2021: $65K · 2022: $55K · 2023: $98K · 2024: $159K · 2025: $269K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $291K · Travel and Lodging: $70K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Honoraria: $45K · Consulting Fee: $44K · Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $291,289.50 |
| Travel and Lodging | $69,857.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $53,186.50 |
| Honoraria | $44,864.00 |
| Consulting Fee | $43,854.25 |
| Food and Beverage | $22,636.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $214,325.14 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $155,010.79 | 2019-2024 | Rexulti, Abilify Mycite, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $98,233.27 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $68,429.54 | 2024-2025 | Cobenfy |
| Noven Pharmaceuticals, INC. | $51,520.04 | 2023-2024 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30,272.07 | 2019-2025 | Rejoyn, Abilify Mycite, Rexulti |
| Axsome Therapeutics, INC. | $25,679.92 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $15,917.96 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $15,876.66 | 2022-2025 | Zurzuvae |
| Neurocrine Biosciences, INC. | $14,942.10 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $6,115.37 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Acadia Pharmaceuticals INC | $6,002.12 | 2019-2025 | Nuplazid |
| Biogen, INC. | $4,818.44 | 2022 | |
| Lundbeck LLC | $2,494.09 | 2020-2025 | Abilify Maintena, Rexulti |
| Noven Therapeutics, LLC | $2,062.50 | 2025 | Xelstrym |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,041.05 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,326.55 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,087.60 | 2019-2025 | Trintellix |
| Corium, LLC | $708.62 | 2022-2024 | Azstarys |
| Tris Pharma INC | $513.99 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $343.63 | 2025 | Austedo Xr, Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.73 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $257.89 | 2019-2022 | |
| Alkermes, INC. | $115.87 | 2022-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $84.61 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $54.48 | 2024 | Lumryz |
| Rhodes Pharmaceuticals L.P. | $19.53 | 2019 | |
| Neuronetics, INC. | $15.11 | 2019 | |
| Livanova USA, INC. | $13.33 | 2021 | |
| Neos Therapeutics, LP | $11.54 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Napoleon Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.